We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Albumedix has extended its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International company.
Albumedix Ltd. completed the expansion of its commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art labs at its UK-based campus in Nottingham.
Novartis will partner with Albumedix, a U.K-based specialist in recombinant human albumin, to explore using the company’s technology as a possible drug delivery platform for several therapies.